Catalyst
Slingshot members are tracking this event:
PEARL trial from AstraZeneca (AZN), which will test durvalumab versus the current standard of care in treatment of breast cancer, to report data 1H 2022
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Future Window:
Jan 01, 2022 - Jun 30, 2022
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Durvalumab, Pearl, Standard Of Care, Lung Cancer
